Cannabis Law Report

FEBRUARY 24, 2022

Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. In January 2022, the FDR statute was amended to give healthcare professionals access to restricted drugs through SAP.

Therapy 52

Therapy Access Clinical Trials Treatment 52

NORML

APRIL 30, 2020

CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” ” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. percent in 2016).”

Chronic Pain 345

Chronic Pain Clinical Trials Data Patients 345

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD 298

CBD Clinical Trials Data Treatment 298

Cannabis Law Report

JANUARY 11, 2022

Legal cannabis partnership to help patient access. The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. UPDATED : Wednesday 12th of January 2022. SYDNEY, AUSTRALIA –.

Access 52

Access Patients Clinical Trials Legalization 52

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 192

Clinical Trials Chronic Pain Data Treatment 192

Veriheal

MARCH 2, 2024

When it comes to cannabis in Japan, the country is known for maintaining strict prohibition and regulation of cannabis-derived products. The revised legislation would permit clinical use and production of cannabis for medical CBD products, like Epidiolex , that have been approved in the U.S.

Legalization 91

Legalization Epilepsy Clinical Trials THC 91

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In part of one of this series, we analyzed the discussions surrounding using cannabis for mental health. In part two, we took a deep look at using cannabis for depression. In part three, we will analyze the available research concerning cannabis and anxiety. Can you use cannabis for anxiety? Cannabis and Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. None of it was initially slated to go to clinical trials. The deadline for proposals is Friday, July 16. Read more at.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

AUGUST 10, 2021

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. For example, the Tuskegee Syphilis Study, wherein Black men were deceived regarding their diagnosis and deprived appropriate treatment over the course of decades.

Clinical Trials 105

Clinical Trials Research and Development Therapy Treatment 105

Cannabis Law Report

JULY 15, 2021

Completion of acquisition provides Creso Pharma with access to the emerging global market for psychedelic medicines – estimated to be worth up to US100Bni. ? Halucenex to progress phase II clinical trial to test the efficacy of psilocybin when used to treat Post Traumatic Stress Disorder (PTSD). ? Highlights: ? The full release.

Clinical Trials 96

Clinical Trials Therapy Treatment Access 96

Veriheal

MARCH 20, 2023

Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Minnesota Rep. Missouri Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 10, 2022

Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. It’s clear that alternative treatment options are necessary to combat depression and other mental illnesses, which is where companies developing psychedelic-based treatments like Optimi Health Corp.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. Following research findings here and abroad, the application sought to have the drugs used as part of psychotherapy treatment for mental illnesses, depression and post-traumatic stress disorder.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures.

Clinical Trials 91

Clinical Trials Research and Development Data Collective 91

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. THC is the psychoactive compound responsible for the “high” associated with marijuana use.

Law 52

Law Dispensary Clinical Trials Programs 52

Cannabis Law Report

NOVEMBER 7, 2021

WA Upper House MP Brian Walker is in the spotlight over potential conflict of interests concerns after he was appointed ‘strategic consultant’ to an ASX-listed medicinal cannabis company. Legalise Cannabis WA MP Brian Walker denies conflict over medicinal cannabis company. Cannabiz reported Friday.

Medicine 52

Medicine Clinical Trials Research and Development Pharmaceutical 52

MMJ Recs

NOVEMBER 20, 2023

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. THC is the primary psychoactive compound in cannabis, responsible for the “high” or euphoric feeling associated with marijuana use.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Veriheal

MAY 26, 2022

With new and improved products popping up left and right, legalization initiatives taking off all over the globe, and harmful “stoner” stigmas quickly dissipating, it’s clear that cannabis has entered a new era. The days of “reefer madness” are long over, replaced by a growing acknowledgment of the cannabis plant’s therapeutic abilities.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

JUNE 24, 2022

The legislation from Senate President Nicholas Scutari (D), who has long championed cannabis reform in the Garden State, would further create a system of licensed businesses to provide psilocybin services in supervised settings. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Medicinal cannabis as a last resort.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The researchers’ analysis found anxiety was the reason given for 16% of medicinal cannabis prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98